参考资料: [1]ArvinasAnnounces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC). Retrieved November 22, 2022 from网页链接 [2] Company Presentation, dated November 21, 2022. Retri...
VERITAC-2: a Phase 3 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER–positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer Mario Campone VERITAC-3 Study Lead-in Trial in...
Tuesday, November 28, 2023 - 05:05pm View pdfcopyCopy to clipboardOpen in tab -- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) --
In the Phase 1 clinical trial in men with mCRPC, ARV-110 continues to show promising activity in a very late-line population, with PSA reductions >50% observed at doses greater than 280 mg, the last reported cohort. In the dose escalation, ARV-110 exposures have risen dose proportionally,...
2022年11月22日讯 /生物谷BIOON/ --Arvinas公司近日公布了ARV-471治疗乳腺癌1/2期研究的2期队列扩展部分(VERITAC)的初步结果(详见:ARV-471: Phase 2 VERITAC Trial Results)。ARV-471是一款新型口服PROTAC®雌激素受体(ER)蛋白降解剂,由辉瑞与Arvinas联合开发,用于治疗局部晚期或转移性雌激素受体阳性/人表皮...
Clinical Trial 分子量 723.90 Formula C45H49N5O4 CAS 号 2229711-68-4 运输条件 Room temperature in continental US; may vary elsewhere. 储存方式 -20°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and...
Here we describe Part C of the phase 1/2 study, which evaluates the safety and clinical activity of ARV-471 plus palbociclib in patients with breast cancer who previously received endocrine therapy. Methods: Eligible patients (aged ≥18 years) have histologically or cytologically confirmed ER+/...
clinical development for ARV-471, whether we will be able to successfully conduct Phase 1/2 clinical trials for ARV-110 and ARV-766, initiate and complete other clinical trials for our product candidates, and receive results from our clinical trials on our expected timeline...
(CBR) in patients with estrogen receptor (ER)–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations, according to expansion cohort analysis from the phase 1/2 VERITAC trial (NCT040...
1 This response was enhanced in a subgroup of patients with ESR1 mutations, according to Anne F. Schott, MD, during a presentation of the data. The phase 2, part B trial evaluated an expansion cohort who received 200 mg of ARV-471 orally, once a day (n = 35) or 500 m...